Twist-BRD4 complex: Potential drug target for basal-like breast cancer

Jian Shi, Jingying Cao, Binhua P. Zhou

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


As an important basic helix-loop-helix (bHLH) transcription factor, Twist associates with several physiological processes such as mesodermal development, and pathological processes such as Saethre-Chotzen syndrome. During cancer progression, Twist induces epithelial-mesenchymal transition (EMT), potentiating cancer cell invasion and metastasis. Although many studies have revealed its multiple biological roles, it remained unclear how Twist transcriptionally acti vates targeted genes. Recently we discovered tip60-mediated Twist di-acetylation in the “histone H4-mimic” GK-X-GK motif. The di-acetylated Twist recruits BRD4 and related transcriptional components to super-enhancer of its targeted genes during progression of basal-like breast cancer (BLBC). Here, we review this new advance of regulation and functional mechanism of Twist.

Original languageEnglish
Pages (from-to)1256-1261
Number of pages6
JournalCurrent Pharmaceutical Design
Issue number10
StatePublished - Jan 1 2015

Bibliographical note

Publisher Copyright:
© 2015 Bentham Science Publishers.


  • BRD4
  • Basal-like breast cancer
  • Epithelial-mesenchymal transition
  • Twist

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Twist-BRD4 complex: Potential drug target for basal-like breast cancer'. Together they form a unique fingerprint.

Cite this